View Clinical Trial (Medical Research Study)

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis - NCT00774852-48201(Clinical Trial 248186)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Detroit
State:  
MI
Zip Code: 48201
Conditions: Lupus Nephritis - Lupus Erythematosus, Systemic
Purpose: This study is for people with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.
Study summary: Lupus nephritis is a kind of kidney inflammation that occurs in patients with systemic lupus erythematosus (SLE). It is caused by the immune system attacking the kidney. It is among the most serious complications of SLE, and left untreated it can cause long term damage to the kidneys or, in some cases, result in kidney failure. One of the more common treatments for lupus nephritis is the "Euro-lupus" therapy. In this therapy, patients receive three different drugs - cyclophosphamide, azathioprine and prednisone - over the course of several months. However, some patients do not respond to this therapy and many only show some improvement. In the ACCESS trial for lupus nephritis, an experimental medication known as abatacept will be added to the Euro-lupus therapy to find out if it works better than Euro-lupus therapy alone. Abatacept is a man-made protein that suppresses parts of the immune system that can cause autoimmune disease. While abatacept is experimental for lupus, it has been approved by the FDA to treat rheumatoid arthritis. It is also being studied for use in other autoimmune diseases, like multiple sclerosis and type 1 diabetes. Participants in the ACCESS trial for lupus nephritis will receive bi-weekly intravenous infusions of cyclophosphamide for 3 months, then will take azathioprine tablets daily for at least 3 months more. Abatacept or a placebo will be administered every 2 weeks at first, then every 4 weeks for at least the first 6 months. Treatment of abatacept or placebo and azathioprine may continue for the remainder of the year. All subjects will take prednisone tablets daily during the whole study. Because the ACCESS trial is a randomized, controlled study, each participant has a 50-50 chance (like flipping a coin) of receiving abatacept. Others will receive an inactive, placebo form of the drug. Note however, that all participants will receive the Euro-lupus therapy. As a blinded study, neither participants nor study physicians will know to which group a person has been assigned. All participants will undergo regular physical examinations, medical history and various blood and urine tests. Many of these tests will be repeated throughout the study. Participants will be asked to attend 18 study visits in the first year, and one study visit at the end of the second year. The study will reimburse participants for certain expenses incurred as part of the study.
Criteria: Inclusion Criteria: - Diagnosis of systemic lupus erythematosus (SLE) by American College of Rheumatology (ACR) criteria - Active lupus nephritis (defined by: kidney biopsy documentation within the last 12 months of ISN/RPS proliferative nephritis, active urinary sediment, urine protein-to-creatinine ratio > 1, low C3) - Positive antinuclear antibody (ANA) test results at time of study entry. Exclusion Criteria: - end stage renal disease - use of cyclophosphamide in the past year - neutropenia, thrombocytopenia, moderately severe anemia - active infection, including HIV, hepatitis B or C - history of cancer, except carcinoma in situ and treated basal and squamous cell carcinomas - pregnant or breastfeeding
Study is available at: Wayne State University
Detroit, MI 48201
United States
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.